Opendata, web and dolomites

EPI-X4Health SIGNED

Therapeutic potential of optimized derivatives of an endogenous CXCR4 antagonist for the treatment of cancers and inflammatory diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EPI-X4Health project word cloud

Explore the words cloud of the EPI-X4Health project. It provides you a very rough idea of what is the project "EPI-X4Health" about.

perform    deregulation    entire    showing    safe    screen    stability    derivatives    arthritis    lung    exists    fragment    parallel    migration    cell    preclinical    ipr    peptide    antagonists    remarkably    cancers    hematopoietic    inhibitor    entry    osteosarcoma    goals    identification    approved    encompassing    linked    mouse    diseases    small    commercialization    inhibits    mice    suggest    naturally    peptidome    agents    invasion    clinical    mobilizes    endogenous    inflammatory    reg    potency    ligands    plasma    models    treatment    compounds    modulating    preliminary    human    cancer    occurring    signaling    plays    disorders    cells    serum    model    blood    asthma    mozobiol    cxcl12    glioblastoma    experimental    coreceptor    prospects    libraries    tolerated    x4    cardiovascular    named    chronic    receptor    pave    synthetic    allowed    therapeutic    colon    blocks    inflammation    potent    tool    efficient    dermatitis    epi    carcinoma    market    stem    amd3100    albumin    antagonist    cxcr4    rheumatoid    hiv    magnitude    strategy    airway    progenitor    orders    chemokine    suppresses   

Project "EPI-X4Health" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAET ULM 

Organization address
address: HELMHOLTZSTRASSE 16
city: ULM
postcode: 89081
website: www.uni-ulm.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 149˙156 €
 EC max contribution 149˙156 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAET ULM DE (ULM) coordinator 95˙256.00
2    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) participant 26˙950.00
3    UNIVERSITE DE STRASBOURG FR (STRASBOURG) participant 26˙950.00

Map

 Project objective

Deregulation of CXCL12 signaling via the CXCR4 chemokine receptor plays a key role in many diseases, including cancer, rheumatoid arthritis, chronic inflammation and cardiovascular disorders. Thus, agents modulating CXCR4 signaling offer many prospects for therapeutic development. CXCR4 is also a major coreceptor for HIV entry. Thus, we used HIV as tool to screen peptide libraries encompassing the entire blood peptidome for novel CXCR4 ligands. This approach allowed the identification of a small fragment of human serum albumin as potent HIV inhibitor. Remarkably, this naturally occurring peptide, named EPI-X4 (Endogenous Peptide Inhibitor of CXCR4), blocks CXCL12/CXCR4 signaling and suppresses cancer cell migration and invasion. Preclinical studies in mice show that EPI-X4 mobilizes hematopoietic stem/progenitor cells and inhibits lung inflammation in an asthma model. Preliminary analyses suggest that EPI-X4 is more specific and better tolerated than Mozobiol® (AMD3100), the only CXCR4 antagonist approved for clinical application. Recently, we developed synthetic derivatives of EPI-X4 showing about three orders of magnitude improved potency against HIV as well as increased plasma stability. Key goals of this project are to determine the therapeutic potential of these improved derivatives against cancers (Aim 1) and inflammatory diseases (Aim 2) using established mouse models of colon carcinoma, osteosarcoma, glioblastoma, airway inflammation and dermatitis. These disorders were selected from the large number of CXCR4-linked diseases because no safe and effective treatment exists and since preclinical mouse models are available to determine whether EPI-X4 derived agents are more efficient and better tolerated than other compounds. In parallel to the experimental assessment of the therapeutic potential of these novel CXCR4 antagonists, we will perform market analyses and develop an IPR strategy to pave the way towards commercialization and future clinical application.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPI-X4HEALTH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPI-X4HEALTH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More  

3DPRINTEDOPTICS (2019)

3D printed micro- and nano-optics for future integrated vision and endoscopy systems

Read More